320 related articles for article (PubMed ID: 8568812)
1. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
3. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
6. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
Aklilu F; Park M; Goltzman D; Rabbani SA
Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
Augeri DJ; O'Connor SJ; Janowick D; Szczepankiewicz B; Sullivan G; Larsen J; Kalvin D; Cohen J; Devine E; Zhang H; Cherian S; Saeed B; Ng SC; Rosenberg S
J Med Chem; 1998 Oct; 41(22):4288-300. PubMed ID: 9784104
[TBL] [Abstract][Full Text] [Related]
8. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.
Hunt JT; Lee VG; Leftheris K; Seizinger B; Carboni J; Mabus J; Ricca C; Yan N; Manne V
J Med Chem; 1996 Jan; 39(2):353-8. PubMed ID: 8558502
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
[TBL] [Abstract][Full Text] [Related]
11. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
[No Abstract] [Full Text] [Related]
12. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
deSolms SJ; Giuliani EA; Graham SL; Koblan KS; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Scholz TH; Wiscount CM; Gibbs JB; Smith RL
J Med Chem; 1998 Jul; 41(14):2651-6. PubMed ID: 9651171
[TBL] [Abstract][Full Text] [Related]
13. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
15. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
[No Abstract] [Full Text] [Related]
16. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
17. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
19. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
Perrin D; Halazy S; Hill B
Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
